Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 5/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795287 | 0.89 | SMN1; SMN2 (0.38) | MTNR1AMTNR1BMAPT | |
| SCHEMBL6205153 | 0.83 | SMN1; SMN2 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4707388 | 0.77 | MAPK14 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4757107 | 0.77 | MAPK14 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4707014 | 0.77 | MAPK14 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4757853 | 0.77 | MAPK14 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4707017 | 0.77 | MAPK14 (0.35) | MTNR1AMTNR1BMAPT | |
| SCHEMBL5831113 | 0.76 | PTK2 (0.44) | PTK2TSPOMAPT | |
| SCHEMBL6207773 | 0.72 | EPHX2 (0.37) | MAPT | |
| SCHEMBL5831934 | 0.69 | PDK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | PTK2 102/4885TSPO 4075/4885MTNR1A 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.